Pharmacyclics announces update on IMBRUVICA Waldenstrom’s macroglobulinemia (WM) submission
IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine